Adventrex Pharmaceuticals,biotch unternehmen mit hohem kurspotential - 500 Beiträge pro Seite (Seite 6)
eröffnet am 21.02.06 13:35:38 von
neuester Beitrag 27.04.10 16:26:04 von
neuester Beitrag 27.04.10 16:26:04 von
Beiträge: 2.656
ID: 1.042.014
ID: 1.042.014
Aufrufe heute: 0
Gesamt: 52.029
Gesamt: 52.029
Aktive User: 0
Top-Diskussionen
Titel | letzter Beitrag | Aufrufe |
---|---|---|
vor 43 Minuten | 1904 | |
08.05.24, 11:56 | 960 | |
11.05.24, 11:52 | 568 | |
vor 1 Stunde | 557 | |
vor 1 Stunde | 512 | |
vor 57 Minuten | 498 | |
gestern 20:02 | 398 | |
vor 1 Stunde | 376 |
Meistdiskutierte Wertpapiere
Platz | vorher | Wertpapier | Kurs | Perf. % | Anzahl | ||
---|---|---|---|---|---|---|---|
1. | 2. | 18.772,96 | -0,01 | 96 | |||
2. | 1. | 0,1985 | -8,53 | 53 | |||
3. | 8. | 10,640 | +2,90 | 32 | |||
4. | 3. | 157,32 | +0,55 | 26 | |||
5. | 4. | 0,1601 | -3,61 | 22 | |||
6. | 6. | 0,2900 | -2,68 | 20 | |||
7. | 5. | 2,3795 | +0,32 | 18 | |||
8. | 9. | 19,598 | +20,92 | 14 |
Antwort auf Beitrag Nr.: 38.832.670 von pagitz01 am 28.01.10 16:38:33Hallo,
bin auch vor 1 Woche raus, um die Gewinne erstmal "eingefahren" zu haben. Woher der Optimismus, daß sich nexm in Kürze verdoppelt ? Mit ANX hattest Du ja Recht.
Bye the way, wen´s interessiert, LABOPHARM könnte in Kürze auch durchstarten. Bis 11.2. soll hier das FDA Approval gegeben werden (oder auch nicht!!). D.h. entweder davor oder bei positiver Entscheidung der FDA könnten hier schnelle Gewinne möglich sein.
bin auch vor 1 Woche raus, um die Gewinne erstmal "eingefahren" zu haben. Woher der Optimismus, daß sich nexm in Kürze verdoppelt ? Mit ANX hattest Du ja Recht.
Bye the way, wen´s interessiert, LABOPHARM könnte in Kürze auch durchstarten. Bis 11.2. soll hier das FDA Approval gegeben werden (oder auch nicht!!). D.h. entweder davor oder bei positiver Entscheidung der FDA könnten hier schnelle Gewinne möglich sein.
0,29$ durchbrochen....scheint ja bei 0,28$ reges Interesse war ja vorhanden...
Antwort auf Beitrag Nr.: 38.835.279 von yxcv1234 am 28.01.10 20:41:51DDSS wird in 2 Wochen auf 4-6 Dollar sein.
hallo sieht auch heute wieder nach lange weile aus.
wer will kannn sich ja mal bei SIRI umschauen.dort brummts zur zeit.
lg
wer will kannn sich ja mal bei SIRI umschauen.dort brummts zur zeit.
lg
so leute bin raus bei nexm mit 5 prozent minus!!!
geht nicht immer!!!!
aber denke es wird trotzdem weiter gehen !!!
bin 100 prozent im cash und warte wieder irgendwo einzusteigen!!!
geht nicht immer!!!!
aber denke es wird trotzdem weiter gehen !!!
bin 100 prozent im cash und warte wieder irgendwo einzusteigen!!!
bin heut auch raus hier und bei wmi rein.komme aber wieder.
volumen derzeit viel zu klein sieht man auch an den langen kerzen im chart.werde mich hier aber wieder einkaufen.bauchgefühl
Antwort auf Beitrag Nr.: 38.843.142 von pagitz01 am 29.01.10 15:40:02DDSS wird in 2 Wochen auf 4-6 Dollar sein
Da mal geguckt ? Oder bei Geely, da bin ich auch drin.
LG Tommi
Da mal geguckt ? Oder bei Geely, da bin ich auch drin.
LG Tommi
.
Im Yahoo-board posten sie weiter wild im Minuten-Takt
und hier is nix Meer los ...
.
Im Yahoo-board posten sie weiter wild im Minuten-Takt
und hier is nix Meer los ...
.
.
M. E. bislang nicht offiziel seitens ANX veröffentlicht:
Laut Teilnehmer-Liste präsentiert sich ANX am
9.2.2010, 10:30 A.M. auf der
BIO CEO & Investor Conference in New York City.
.
M. E. bislang nicht offiziel seitens ANX veröffentlicht:
Laut Teilnehmer-Liste präsentiert sich ANX am
9.2.2010, 10:30 A.M. auf der
BIO CEO & Investor Conference in New York City.
.
.
aber muss wohl noch x runta
.
aber muss wohl noch x runta
.
Auf der Adventrx Homepage:
Press Release
ADVENTRX Pharmaceuticals to Present at the 12th Annual BIO CEO & Investor Conference on February 9
SAN DIEGO, Feb 02, 2010 /PRNewswire via COMTEX/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) today announced that the Company's Principal Executive Officer, Brian M. Culley, will present at the 12th Annual BIO CEO & Investor Conference on Tuesday, February 9, 2010, at 10:30 a.m. Eastern time, in the Park South room at the Waldorf Astoria in New York. The conference is being hosted by the Biotechnology Industry Association.
Interested parties can access a live audio webcast and slide presentation on the ADVENTRX Pharmaceuticals Web site at www.adventrx.com. An archived presentation will be available on the Web site for 30 days.
About ADVENTRX Pharmaceuticals
ADVENTRX Pharmaceuticals is a specialty pharmaceutical company whose product candidates are designed to improve the performance of existing cancer treatments by addressing limitations associated principally with their safety and use. More information can be found on the Company's Web site at www.adventrx.com.
SOURCE ADVENTRX Pharmaceuticals, Inc.
Press Release
ADVENTRX Pharmaceuticals to Present at the 12th Annual BIO CEO & Investor Conference on February 9
SAN DIEGO, Feb 02, 2010 /PRNewswire via COMTEX/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) today announced that the Company's Principal Executive Officer, Brian M. Culley, will present at the 12th Annual BIO CEO & Investor Conference on Tuesday, February 9, 2010, at 10:30 a.m. Eastern time, in the Park South room at the Waldorf Astoria in New York. The conference is being hosted by the Biotechnology Industry Association.
Interested parties can access a live audio webcast and slide presentation on the ADVENTRX Pharmaceuticals Web site at www.adventrx.com. An archived presentation will be available on the Web site for 30 days.
About ADVENTRX Pharmaceuticals
ADVENTRX Pharmaceuticals is a specialty pharmaceutical company whose product candidates are designed to improve the performance of existing cancer treatments by addressing limitations associated principally with their safety and use. More information can be found on the Company's Web site at www.adventrx.com.
SOURCE ADVENTRX Pharmaceuticals, Inc.
Antwort auf Beitrag Nr.: 38.864.681 von Lizu am 02.02.10 16:59:54
intressante news noch keiner gesehen oder versteht keiner was das heissen könnte!!!!!
sieht gut aus aber nicht gleich kaufen bei eröffnung erst beruhigen lassen kaufen ohne gap!!!
sieht gut aus aber nicht gleich kaufen bei eröffnung erst beruhigen lassen kaufen ohne gap!!!
Antwort auf Beitrag Nr.: 38.871.700 von pagitz01 am 03.02.10 14:22:49läuft wohl wieder hoch, pre markt sind auch nicht schlecht aus
Antwort auf Beitrag Nr.: 38.871.708 von wave1984 am 03.02.10 14:24:03Pre-Market
Last: $ .3419 Pre-Market
High: $ .36
Pre-Market
Volume: 944,532 Pre-Market
Low: $ .33
Last: $ .3419 Pre-Market
High: $ .36
Pre-Market
Volume: 944,532 Pre-Market
Low: $ .33
Antwort auf Beitrag Nr.: 38.871.708 von wave1984 am 03.02.10 14:24:03volumen nicht übel
Antwort auf Beitrag Nr.: 38.871.752 von wave1984 am 03.02.10 14:28:38sieht gut aus heute.technisch steht auch alles auf grün.anx goes up!
Antwort auf Beitrag Nr.: 38.871.708 von wave1984 am 03.02.10 14:24:03
bin im moment nicht dabei bin mal rein in ddss vor ein paar tagen erhoffe mir mal 6 usd un dann aber je nach kurs und umfeld wieder zurück in anx wie gesagt meine 2 usd die werden schon kommen!!!
bin im moment nicht dabei bin mal rein in ddss vor ein paar tagen erhoffe mir mal 6 usd un dann aber je nach kurs und umfeld wieder zurück in anx wie gesagt meine 2 usd die werden schon kommen!!!
Antwort auf Beitrag Nr.: 38.871.871 von pagitz01 am 03.02.10 14:42:53ich bin auch nicht drin
Antwort auf Beitrag Nr.: 38.871.871 von pagitz01 am 03.02.10 14:42:53ddss ???
Pre-Market:
0,34 USD Vol. 1.739.232
ziemlich stark
0,34 USD Vol. 1.739.232
ziemlich stark
ADVENTRX Appoints Icahn Representative to Board of Directors
ADVENTRX Appoints Icahn Representative to Board of Directors
Feb. 3, 2010 (PR Newswire) -- ADVENTRX Appoints Icahn Representative to Board of Directors
SAN DIEGO -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) today announced that Odysseas D. Kostas, M.D. will join its Board of Directors. Dr. Kostas also will serve on the Board's Audit Committee. Dr. Kostas was appointed as the representative of entities affiliated with Carl C. Icahn.
"We are delighted to welcome Odysseas to our Board of Directors," said Jack Lief, Chair of the ADVENTRX Board of Directors and the Board's Audit Committee. "His insights should prove valuable as we advance our product candidates towards commercialization."
Dr. Kostas, M.D. is an attending physician and one of seven hospitalists at Greenwich Hospital, a member of the Yale New Haven Health System and a subsidiary of Greenwich Health Care Services, Inc. At Greenwich Hospital, Dr. Kostas is a member of various committees that oversee aspects of the hospital's operational decision-making. Since March 2007, Dr. Kostas has provided advisory services to Boards of Directors of biotechnology companies, primarily in the area of strategic and partnering transactions, including ImClone Systems Incorporated prior to its sale to Eli Lilly and Company. In May 2003, Dr. Kostas founded a private medical practice that he owned and operated, treating over 2,000 patients, until May 2008. Dr. Kostas holds a B.S. in biology from the Massachusetts Institute of Technology and an M.D. from the University of Texas Southwestern Medical School and is board certified in internal medicine.
About ADVENTRX Pharmaceuticals
ADVENTRX Pharmaceuticals is a specialty pharmaceutical company whose product candidates are designed to improve the performance of existing cancer treatments by addressing limitations associated principally with their safety and use. More information can be found on ADVENTRX's web site at www.adventrx.com.
Forward Looking Statements
ADVENTRX cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks and assumptions that, if they materialize or do not prove to be accurate, could cause ADVENTRX's results to differ materially from historical results or those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: successfully educating new directors and integrating new directors with existing directors and management; the risk that directors' will undertake projects that divert their respective attention from ADVENTRX matters, or that may pose a conflict of interest with ADVENTRX; ADVENTRX's dependence on the success of ANX-530, and uncertainty as to whether ANX-530 will receive regulatory approval or be commercialized successfully; the potential that FDA may not accept the ANX-530 NDA for review, or that the bioequivalence data and other information included in the ANX-530 NDA may not adequately support bioequivalence with Navelbine, including as a result of performing pharmacokinetic equivalence analyses based on a patient population other than the population on which ADVENTRX based its analysis; the potential that changes made in transferring the manufacturing process for ANX-530 may result in a lack of comparability between the commercial product and the material used in clinical trials, and that FDA may require ADVENTRX to perform additional non-clinical or clinical studies; and other risks and uncertainties more fully described in ADVENTRX's press releases and periodic filings with the Securities and Exchange Commission. ADVENTRX's public filings with the Securities and Exchange Commission are available at www.sec.gov.
You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date when made. ADVENTRX does not intend to revise or update any forward-looking statement set forth in this press release to reflect events or circumstances arising after the date on which it was made.
SOURCE ADVENTRX Pharmaceuticals, Inc.
Source: PR Newswire (February 3, 2010 - 8:02 AM EST)
News by QuoteMedia
ADVENTRX Appoints Icahn Representative to Board of Directors
Feb. 3, 2010 (PR Newswire) -- ADVENTRX Appoints Icahn Representative to Board of Directors
SAN DIEGO -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) today announced that Odysseas D. Kostas, M.D. will join its Board of Directors. Dr. Kostas also will serve on the Board's Audit Committee. Dr. Kostas was appointed as the representative of entities affiliated with Carl C. Icahn.
"We are delighted to welcome Odysseas to our Board of Directors," said Jack Lief, Chair of the ADVENTRX Board of Directors and the Board's Audit Committee. "His insights should prove valuable as we advance our product candidates towards commercialization."
Dr. Kostas, M.D. is an attending physician and one of seven hospitalists at Greenwich Hospital, a member of the Yale New Haven Health System and a subsidiary of Greenwich Health Care Services, Inc. At Greenwich Hospital, Dr. Kostas is a member of various committees that oversee aspects of the hospital's operational decision-making. Since March 2007, Dr. Kostas has provided advisory services to Boards of Directors of biotechnology companies, primarily in the area of strategic and partnering transactions, including ImClone Systems Incorporated prior to its sale to Eli Lilly and Company. In May 2003, Dr. Kostas founded a private medical practice that he owned and operated, treating over 2,000 patients, until May 2008. Dr. Kostas holds a B.S. in biology from the Massachusetts Institute of Technology and an M.D. from the University of Texas Southwestern Medical School and is board certified in internal medicine.
About ADVENTRX Pharmaceuticals
ADVENTRX Pharmaceuticals is a specialty pharmaceutical company whose product candidates are designed to improve the performance of existing cancer treatments by addressing limitations associated principally with their safety and use. More information can be found on ADVENTRX's web site at www.adventrx.com.
Forward Looking Statements
ADVENTRX cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks and assumptions that, if they materialize or do not prove to be accurate, could cause ADVENTRX's results to differ materially from historical results or those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: successfully educating new directors and integrating new directors with existing directors and management; the risk that directors' will undertake projects that divert their respective attention from ADVENTRX matters, or that may pose a conflict of interest with ADVENTRX; ADVENTRX's dependence on the success of ANX-530, and uncertainty as to whether ANX-530 will receive regulatory approval or be commercialized successfully; the potential that FDA may not accept the ANX-530 NDA for review, or that the bioequivalence data and other information included in the ANX-530 NDA may not adequately support bioequivalence with Navelbine, including as a result of performing pharmacokinetic equivalence analyses based on a patient population other than the population on which ADVENTRX based its analysis; the potential that changes made in transferring the manufacturing process for ANX-530 may result in a lack of comparability between the commercial product and the material used in clinical trials, and that FDA may require ADVENTRX to perform additional non-clinical or clinical studies; and other risks and uncertainties more fully described in ADVENTRX's press releases and periodic filings with the Securities and Exchange Commission. ADVENTRX's public filings with the Securities and Exchange Commission are available at www.sec.gov.
You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date when made. ADVENTRX does not intend to revise or update any forward-looking statement set forth in this press release to reflect events or circumstances arising after the date on which it was made.
SOURCE ADVENTRX Pharmaceuticals, Inc.
Source: PR Newswire (February 3, 2010 - 8:02 AM EST)
News by QuoteMedia
Antwort auf Beitrag Nr.: 38.871.949 von wave1984 am 03.02.10 14:52:08
ja labopharm!!!!
ddss
bei nexm bin ich raus mit 5 prozet minus!!!
ja labopharm!!!!
ddss
bei nexm bin ich raus mit 5 prozet minus!!!
Antwort auf Beitrag Nr.: 38.872.316 von pagitz01 am 03.02.10 15:32:31ok danke
da ist was drin, aber die frage ist wieviel
da ist was drin, aber die frage ist wieviel
Antwort auf Beitrag Nr.: 38.872.356 von wave1984 am 03.02.10 15:36:20
naja fda zulassung in einem 11 billionen markt!!!
kannst ja ma rechnen anfangen was da für eine mkp im normalfall okay wäre!!!
alle anxler können sich heute aber wieder freuen is ne gute news!!!
naja fda zulassung in einem 11 billionen markt!!!
kannst ja ma rechnen anfangen was da für eine mkp im normalfall okay wäre!!!
alle anxler können sich heute aber wieder freuen is ne gute news!!!
Antwort auf Beitrag Nr.: 38.872.392 von pagitz01 am 03.02.10 15:39:08wird glaube ich am 11.02.2010 entschieden oder?
Sollte die Zulassung kommen $5 möglich
Sollte die Zulassung kommen $5 möglich
Antwort auf Beitrag Nr.: 38.871.949 von wave1984 am 03.02.10 14:52:08DDSS ist ein Wert wo mal wieder schön abgezockt wird da konnteste heut gleich mal rund 25 % in den Sand setzen...alles wo User " Brauch Geld " drin ist....wird abgezockt-fertig..und auch Peterchen ist auf den Leim gegangen...thats life
Ich bleib schön hier bei ANX. Hier wird es einen schönen Schub geben die nächsten 2-3 Monate und dann gibts 1$ +x.
Sei es pps oder durch eine Übernahme. Aber noch bevor sich der Schnee aus D getrollt haben wird wird es hier schön mollig warm werden.
Die Meldung mit dem neuen Board Member ist genau der richtige Fingerzeig.
Sei es pps oder durch eine Übernahme. Aber noch bevor sich der Schnee aus D getrollt haben wird wird es hier schön mollig warm werden.
Die Meldung mit dem neuen Board Member ist genau der richtige Fingerzeig.
Antwort auf Beitrag Nr.: 38.864.681 von Lizu am 02.02.10 16:59:54Ja und wenn wieder alle auf meganews warten und diese nicht kommen werden alle enttäuscht sein. Alle denken das sie sagen Medikament kommt etc. Oder was erhoffen sich alle immer von den conferencen
WEnn ich es richtie sehe, dann haben alle "wichtigen" Insider die Optionen hielten diese am 2.2 vollständig eingelöst
z.B:
http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=6734…
D.h. über 4 Mio Shares wurden von Insindern zu 0,32$ gezogen. Ich glaube nicht das die die Shares für 0,35$ auf den MArkt werfen werden wollen.
z.B:
http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=6734…
D.h. über 4 Mio Shares wurden von Insindern zu 0,32$ gezogen. Ich glaube nicht das die die Shares für 0,35$ auf den MArkt werfen werden wollen.
Der Dollar kommt.
Dr. Kostas - Ichan's board member: 133,332
CEO Culley: 1.6 millionen
Jack Lief: 200,000
Patrick Keran: 1.6 millionen
Michael Goldberg: 200,000
Eric Rowinsky: 200,000
Mark Pykett: 200,000
Wer würde für 450.000 $ Optionen kaufen, wenn nicht was im in der Pipeline ist? Noch dazu alle gleichzeitig.
CEO Culley: 1.6 millionen
Jack Lief: 200,000
Patrick Keran: 1.6 millionen
Michael Goldberg: 200,000
Eric Rowinsky: 200,000
Mark Pykett: 200,000
Wer würde für 450.000 $ Optionen kaufen, wenn nicht was im in der Pipeline ist? Noch dazu alle gleichzeitig.
OK, ich war wohl noch etwas müde heute morgen. Die Optionen wurden nicht gezogen, sondern zusätzlich ausgegeben.
Allerdings, auch das sagt einiges aus über die anzunehmende Entwicklung
Allerdings, auch das sagt einiges aus über die anzunehmende Entwicklung
Antwort auf Beitrag Nr.: 38.872.392 von pagitz01 am 03.02.10 15:39:08Der Markt ist riesig, der Wettbwerb aber auch. Es gibt bereits Gernerika auf diesem Markt, da braucht keiner wirklich die teurere DDSS-Lösung. Deshalb muss man halt etwas DD durchführen, wenn in Biotech investiert wird.
Bei ANX können die Wirkstoffe großen Firmen etwas abnehmen, was natürlich auch keine einfache Aufgabe ist Dennoch besteht hier die Möglichkeit, dass ein großer sagt, den nehme ich mit oder beteilige mich früh dran, so kann die Entwicklung verfolgt werden.
Die ANX-Chancen stehen nicht schlecht......
Gruß
KLR
Bei ANX können die Wirkstoffe großen Firmen etwas abnehmen, was natürlich auch keine einfache Aufgabe ist Dennoch besteht hier die Möglichkeit, dass ein großer sagt, den nehme ich mit oder beteilige mich früh dran, so kann die Entwicklung verfolgt werden.
Die ANX-Chancen stehen nicht schlecht......
Gruß
KLR
Könnte heut eher hoch gehen !?
Wieder ein neuer Bericht.
ADVENTRX Announces Management Promotions
SAN DIEGO, Feb 04, 2010 /PRNewswire via COMTEX/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) today announced that, effective immediately, Brian M. Culley, previously the Company's Chief Business Officer and a Senior Vice President, will serve as its Chief Executive Officer and Patrick L. Keran, previously the Company's General Counsel, will serve as its President and Chief Operating Officer. Mr. Keran also will continue to serve as the Company's Secretary and Principal Financial and Accounting Officer.
"The title changes we announce today are well-deserved and reflect the responsibilities and operational influence that Brian and Pat assumed some time ago," said Jack Lief, Chair of the ADVENTRX Board of Directors. "The Board has confidence in their strategic planning and ability to execute, evidenced in part by their capital-raising success and the submission of the ANX-530 NDA, all during extremely difficult times."
About ADVENTRX Pharmaceuticals
ADVENTRX Pharmaceuticals is a specialty pharmaceutical company whose product candidates are designed to improve the performance of existing cancer treatments by addressing limitations associated principally with their safety and use. More information can be found on the Company's web site at www.adventrx.com.
Forward Looking Statements
ADVENTRX cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks and assumptions that, if they materialize or do not prove to be accurate, could cause ADVENTRX's results to differ materially from historical results or those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: ADVENTRX's dependence on the success of ANX-530, and uncertainty as to whether ANX-530 will receive regulatory approval or be commercialized successfully; the potential that FDA may not accept the ANX-530 NDA for review, or that the bioequivalence data and other information included in the ANX-530 NDA may not adequately support bioequivalence with Navelbine; the potential that changes made in transferring the manufacturing process for ANX-530 may result in a lack of comparability between the commercial product and the material used in clinical trials; the potential for FDA to impose other requirements to be completed before or after approval of the ANX-530 NDA; the possibility that patent claims covering ANX-530 will not issue or, if they do, that such claims, which likely will be limited to a specific intravenous emulsion formulation of vinorelbine, will not be sufficient to preclude development of other formulations of vinorelbine by competitors; the risk of investigator bias in reporting adverse events as a result of the open-label nature of the ANX-530 bioequivalence study, including bias that increased the reporting of adverse events associated with Navelbine and/or that decreased the reporting of adverse events associated with ANX-530; and other risks and uncertainties more fully described in ADVENTRX's press releases and periodic filings with the Securities and Exchange Commission. ADVENTRX's public filings with the Securities and Exchange Commission are available at www.sec.gov.
You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date when made. ADVENTRX does not intend to revise or update any forward-looking statement set forth in this press release to reflect events or circumstances arising after the date on which it was made.
SOURCE ADVENTRX Pharmaceuticals, Inc.
ADVENTRX Announces Management Promotions
SAN DIEGO, Feb 04, 2010 /PRNewswire via COMTEX/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) today announced that, effective immediately, Brian M. Culley, previously the Company's Chief Business Officer and a Senior Vice President, will serve as its Chief Executive Officer and Patrick L. Keran, previously the Company's General Counsel, will serve as its President and Chief Operating Officer. Mr. Keran also will continue to serve as the Company's Secretary and Principal Financial and Accounting Officer.
"The title changes we announce today are well-deserved and reflect the responsibilities and operational influence that Brian and Pat assumed some time ago," said Jack Lief, Chair of the ADVENTRX Board of Directors. "The Board has confidence in their strategic planning and ability to execute, evidenced in part by their capital-raising success and the submission of the ANX-530 NDA, all during extremely difficult times."
About ADVENTRX Pharmaceuticals
ADVENTRX Pharmaceuticals is a specialty pharmaceutical company whose product candidates are designed to improve the performance of existing cancer treatments by addressing limitations associated principally with their safety and use. More information can be found on the Company's web site at www.adventrx.com.
Forward Looking Statements
ADVENTRX cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks and assumptions that, if they materialize or do not prove to be accurate, could cause ADVENTRX's results to differ materially from historical results or those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: ADVENTRX's dependence on the success of ANX-530, and uncertainty as to whether ANX-530 will receive regulatory approval or be commercialized successfully; the potential that FDA may not accept the ANX-530 NDA for review, or that the bioequivalence data and other information included in the ANX-530 NDA may not adequately support bioequivalence with Navelbine; the potential that changes made in transferring the manufacturing process for ANX-530 may result in a lack of comparability between the commercial product and the material used in clinical trials; the potential for FDA to impose other requirements to be completed before or after approval of the ANX-530 NDA; the possibility that patent claims covering ANX-530 will not issue or, if they do, that such claims, which likely will be limited to a specific intravenous emulsion formulation of vinorelbine, will not be sufficient to preclude development of other formulations of vinorelbine by competitors; the risk of investigator bias in reporting adverse events as a result of the open-label nature of the ANX-530 bioequivalence study, including bias that increased the reporting of adverse events associated with Navelbine and/or that decreased the reporting of adverse events associated with ANX-530; and other risks and uncertainties more fully described in ADVENTRX's press releases and periodic filings with the Securities and Exchange Commission. ADVENTRX's public filings with the Securities and Exchange Commission are available at www.sec.gov.
You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date when made. ADVENTRX does not intend to revise or update any forward-looking statement set forth in this press release to reflect events or circumstances arising after the date on which it was made.
SOURCE ADVENTRX Pharmaceuticals, Inc.
Und noch einer.Beide auf der Homepage veröffentlicht.
ADVENTRX Appoints Icahn Representative to Board of Directors
SAN DIEGO, Feb 03, 2010 /PRNewswire via COMTEX/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) today announced that Odysseas D. Kostas, M.D. will join its Board of Directors. Dr. Kostas also will serve on the Board's Audit Committee. Dr. Kostas was appointed as the representative of entities affiliated with Carl C. Icahn.
"We are delighted to welcome Odysseas to our Board of Directors," said Jack Lief, Chair of the ADVENTRX Board of Directors and the Board's Audit Committee. "His insights should prove valuable as we advance our product candidates towards commercialization."
Dr. Kostas, M.D. is an attending physician and one of seven hospitalists at Greenwich Hospital, a member of the Yale New Haven Health System and a subsidiary of Greenwich Health Care Services, Inc. At Greenwich Hospital, Dr. Kostas is a member of various committees that oversee aspects of the hospital's operational decision-making. Since March 2007, Dr. Kostas has provided advisory services to Boards of Directors of biotechnology companies, primarily in the area of strategic and partnering transactions, including ImClone Systems Incorporated prior to its sale to Eli Lilly and Company. In May 2003, Dr. Kostas founded a private medical practice that he owned and operated, treating over 2,000 patients, until May 2008. Dr. Kostas holds a B.S. in biology from the Massachusetts Institute of Technology and an M.D. from the University of Texas Southwestern Medical School and is board certified in internal medicine.
About ADVENTRX Pharmaceuticals
ADVENTRX Pharmaceuticals is a specialty pharmaceutical company whose product candidates are designed to improve the performance of existing cancer treatments by addressing limitations associated principally with their safety and use. More information can be found on ADVENTRX's web site at http://www.adventrx.com/.
Forward Looking Statements
ADVENTRX cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks and assumptions that, if they materialize or do not prove to be accurate, could cause ADVENTRX's results to differ materially from historical results or those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: successfully educating new directors and integrating new directors with existing directors and management; the risk that directors' will undertake projects that divert their respective attention from ADVENTRX matters, or that may pose a conflict of interest with ADVENTRX; ADVENTRX's dependence on the success of ANX-530, and uncertainty as to whether ANX-530 will receive regulatory approval or be commercialized successfully; the potential that FDA may not accept the ANX-530 NDA for review, or that the bioequivalence data and other information included in the ANX-530 NDA may not adequately support bioequivalence with Navelbine, including as a result of performing pharmacokinetic equivalence analyses based on a patient population other than the population on which ADVENTRX based its analysis; the potential that changes made in transferring the manufacturing process for ANX-530 may result in a lack of comparability between the commercial product and the material used in clinical trials, and that FDA may require ADVENTRX to perform additional non-clinical or clinical studies; and other risks and uncertainties more fully described in ADVENTRX's press releases and periodic filings with the Securities and Exchange Commission. ADVENTRX's public filings with the Securities and Exchange Commission are available at http://www.sec.gov/.
You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date when made. ADVENTRX does not intend to revise or update any forward-looking statement set forth in this press release to reflect events or circumstances arising after the date on which it was made.
SOURCE ADVENTRX Pharmaceuticals, Inc.
ADVENTRX Appoints Icahn Representative to Board of Directors
SAN DIEGO, Feb 03, 2010 /PRNewswire via COMTEX/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) today announced that Odysseas D. Kostas, M.D. will join its Board of Directors. Dr. Kostas also will serve on the Board's Audit Committee. Dr. Kostas was appointed as the representative of entities affiliated with Carl C. Icahn.
"We are delighted to welcome Odysseas to our Board of Directors," said Jack Lief, Chair of the ADVENTRX Board of Directors and the Board's Audit Committee. "His insights should prove valuable as we advance our product candidates towards commercialization."
Dr. Kostas, M.D. is an attending physician and one of seven hospitalists at Greenwich Hospital, a member of the Yale New Haven Health System and a subsidiary of Greenwich Health Care Services, Inc. At Greenwich Hospital, Dr. Kostas is a member of various committees that oversee aspects of the hospital's operational decision-making. Since March 2007, Dr. Kostas has provided advisory services to Boards of Directors of biotechnology companies, primarily in the area of strategic and partnering transactions, including ImClone Systems Incorporated prior to its sale to Eli Lilly and Company. In May 2003, Dr. Kostas founded a private medical practice that he owned and operated, treating over 2,000 patients, until May 2008. Dr. Kostas holds a B.S. in biology from the Massachusetts Institute of Technology and an M.D. from the University of Texas Southwestern Medical School and is board certified in internal medicine.
About ADVENTRX Pharmaceuticals
ADVENTRX Pharmaceuticals is a specialty pharmaceutical company whose product candidates are designed to improve the performance of existing cancer treatments by addressing limitations associated principally with their safety and use. More information can be found on ADVENTRX's web site at http://www.adventrx.com/.
Forward Looking Statements
ADVENTRX cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks and assumptions that, if they materialize or do not prove to be accurate, could cause ADVENTRX's results to differ materially from historical results or those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: successfully educating new directors and integrating new directors with existing directors and management; the risk that directors' will undertake projects that divert their respective attention from ADVENTRX matters, or that may pose a conflict of interest with ADVENTRX; ADVENTRX's dependence on the success of ANX-530, and uncertainty as to whether ANX-530 will receive regulatory approval or be commercialized successfully; the potential that FDA may not accept the ANX-530 NDA for review, or that the bioequivalence data and other information included in the ANX-530 NDA may not adequately support bioequivalence with Navelbine, including as a result of performing pharmacokinetic equivalence analyses based on a patient population other than the population on which ADVENTRX based its analysis; the potential that changes made in transferring the manufacturing process for ANX-530 may result in a lack of comparability between the commercial product and the material used in clinical trials, and that FDA may require ADVENTRX to perform additional non-clinical or clinical studies; and other risks and uncertainties more fully described in ADVENTRX's press releases and periodic filings with the Securities and Exchange Commission. ADVENTRX's public filings with the Securities and Exchange Commission are available at http://www.sec.gov/.
You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date when made. ADVENTRX does not intend to revise or update any forward-looking statement set forth in this press release to reflect events or circumstances arising after the date on which it was made.
SOURCE ADVENTRX Pharmaceuticals, Inc.
Antwort auf Beitrag Nr.: 38.877.581 von klr am 04.02.10 10:12:50
kann mich grad nicht erinnern das ich dich um hilfe gebeten habe???!!!oder meinungen!!!
ich nehme mal an du bist in anx investiert dann für mich eh logo das anx die bessere wahl ist!!!
ich war schon in anx hab einen trade versucht bei nexm und ddss beides im minus aber rechtzeitig gestopt!!!
nun schau ich mal zu bei allen titeln!!!
und anx wird schon bald wieder auf meiner kaufliste stehen!!!
kann mich grad nicht erinnern das ich dich um hilfe gebeten habe???!!!oder meinungen!!!
ich nehme mal an du bist in anx investiert dann für mich eh logo das anx die bessere wahl ist!!!
ich war schon in anx hab einen trade versucht bei nexm und ddss beides im minus aber rechtzeitig gestopt!!!
nun schau ich mal zu bei allen titeln!!!
und anx wird schon bald wieder auf meiner kaufliste stehen!!!
Alle eingeschlafen
guten morgen.
neue woche neues glück.hier mal eine techn.analyse die ich so unterschreiben würde.
http://www.youtube.com/watch?v=QP_tkPguCUI
die nächsten 2 wochen werdens bringen.
viel glück allen.
neue woche neues glück.hier mal eine techn.analyse die ich so unterschreiben würde.
http://www.youtube.com/watch?v=QP_tkPguCUI
die nächsten 2 wochen werdens bringen.
viel glück allen.
Antwort auf Beitrag Nr.: 38.948.300 von teich61 am 16.02.10 07:55:57hab ne neue perle.ccz
Wer hat heute für 24 C in Frankfurt eingekauft (+26 %) ?
Kommen heute Nachmittag noch News oder Limit vergessen
Kommen heute Nachmittag noch News oder Limit vergessen
Das selbe habe ich mich auch gefragt!?
Weiß da jemand mehr als wir!?
Lg Lizu
Weiß da jemand mehr als wir!?
Lg Lizu
1000 Stück a 0,24 sind atemberaubende 240 Euro. Ich glaub nicht das da einer mehr weiß
Ja .... trotzdem!
heute startschuss??
sieht fast so aus,
Na dann bin ja mal gespannt obs heute weiter geht ;-)
Was war das denn ?
Das würde ich auch mal gerne wissen!?
Ist da was im Busch!?
Lg
Ist da was im Busch!?
Lg
Antwort auf Beitrag Nr.: 38.973.329 von Lizu am 19.02.10 12:36:24.....ist da was im busch?
ja na sicher , der gestrige verlauf ist doch nicht normal gewesen.im obrigen chart prima zu sehen.
mfg
ja na sicher , der gestrige verlauf ist doch nicht normal gewesen.im obrigen chart prima zu sehen.
mfg
Antwort auf Beitrag Nr.: 38.973.508 von teich61 am 19.02.10 12:57:55...ich denke auch da kommt was heute
Antwort auf Beitrag Nr.: 38.973.744 von vopa77 am 19.02.10 13:27:54und was soll denn kommen
hier eine aktuelle techn.analyse !
http://www.viddler.com/explore/zigzagman/videos/5/
mfg und viel erfolg
http://www.viddler.com/explore/zigzagman/videos/5/
mfg und viel erfolg
sorry so natürlich...
http://www.viddler.com/explore/zigzagman/videos/5/
http://www.viddler.com/explore/zigzagman/videos/5/
Wieder eine bestätigung das diese Aktie müll ist ..
http://finance.yahoo.com/news/ADVENTRX-Receives-Refuse-to-pr…
http://finance.yahoo.com/news/ADVENTRX-Receives-Refuse-to-pr…
Muss man schauen wie der Markt reagiert. Im premarket wurden gerade mal 3-5 trades gemacht bei minimal volumen 1000 shares.
Ausserdem verstehe ich das das die FDA zusätzliche infos benötigt. Das berechtigt meiner Meinung nach nicht den aktuellen Kurs
Ausserdem verstehe ich das das die FDA zusätzliche infos benötigt. Das berechtigt meiner Meinung nach nicht den aktuellen Kurs
Das ist übel, da macht die novelos-Angst die Kurse. In Stuttgart hat einer 24.000 Stück für 7! Cent geschmissen. Ich denke, daß ist doch etwas überzogen, aber wer weiß
Kann jemand die Press release mal kurz und knackig übersetzen?
Vielen Dank schonmal!
Lg Lizu
Vielen Dank schonmal!
Lg Lizu
ich hoffe ihr könnte euch noch dran erinnern, was ich hier, mitte Januar geschrieben habe, alle die nicht gehört haben sind jetzt selber schuld
Antwort auf Beitrag Nr.: 39.032.352 von wave1984 am 01.03.10 13:18:08überflüssig wie ein Kropf Dein Posting, hat was von Besserwisserei und Genugtuung.......
Antwort auf Beitrag Nr.: 39.032.548 von fohlenpelzig am 01.03.10 13:43:52damals wurde ich hier von alle seiten runter gemacht, deswegen habe ich das nochmal geschrieben
Pre-Market von 17 Cent auf 20 Cent. Bin mal gespannt zu welchen Kursen es dann wirklich in ner Stunde losgeht.
die zu 7 cent hätt ich sofort gekauft...
gehts heute los?
Autsch..ist aber auch heftig hier !
ADVENTRX Receives Refuse to File Letter from FDA on ANX-530 New Drug Application:
http://finance.yahoo.com/news/ADVENTRX-Receives-Refuse-to-pr…
Press Release Source: ADVENTRX Pharmaceuticals, Inc.
On Monday March 1, 2010, 1:00 am
SAN DIEGO, March 1 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) announced today that it received a refuse to file letter from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for ANX-530 (vinorelbine injectable emulsion). In the letter, the FDA indicated that the data included in the initial submission from the intended commercial manufacturing site was insufficient to support a commercially-viable expiration dating period. FDA identified only the one chemistry, manufacturing and controls (CMC) reason for the refusal to file. ADVENTRX plans to meet with the FDA as soon as possible to discuss its response.
To support a commercially-viable expiration dating period, the stability data provided in the ANX-530 NDA met ICH filing requirements for a new drug. Site-specific stability data from lots manufactured at the intended commercial manufacturing site also were submitted in the NDA.
"We believed, following discussions with the FDA at a pre-NDA meeting, the stability data package included in our initial submission supported both NDA acceptance and appropriate expiration dating. However, we now expect FDA will require additional site-specific stability data to accept our application. Although we plan to discuss the particular filing requirements with the reviewing chemists, site-specific stability studies are already ongoing and our recent financings provide us the capital to continue this work and, we expect, resubmit the application," said Brian M. Culley, Chief Executive Officer at ADVENTRX.
"We will work closely with the Agency to understand its new requirements and define the path to a successful resubmission at the earliest possible time," Mr. Culley continued.
ADVENTRX submitted the NDA for ANX-530 on December 30, 2009. Based on current regulations, once an NDA is submitted to the FDA, FDA has 60 days to preliminarily review the NDA submission and assess whether the NDA is sufficiently complete to permit a substantive review. If it determines that the NDA is not sufficiently complete, the FDA issues a refuse to file letter to the applicant. ADVENTRX plans to request a meeting with the FDA as soon as possible to discuss its comments on the NDA submission and to reach an understanding on what would be required for the ANX-530 NDA to be accepted for review.
Conference Call and Webcast
ADVENTRX will hold a conference call on Monday, March 1, 2010 beginning at 9:00 a.m. Eastern time to review the developments discussed in this news release. Individuals interested in listening to the conference call may do so by dialing (866) 305-6438 for domestic callers, or (706) 679-7161 for international callers, or from the webcast on the investor relations section of the Company's Web site at www.adventrx.com. A 48-hour telephone replay will be available approximately one hour after the conclusion of the call by dialing (800) 642-1687 for domestic callers, or (706) 645-9291 for international callers, and entering reservation code 60223016. The webcast will be available on the Company's Web site for 14 days following the completion of the call.
http://investorshub.advfn.com/boards/read_msg.aspx?message_i…
http://finance.yahoo.com/news/ADVENTRX-Receives-Refuse-to-pr…
Press Release Source: ADVENTRX Pharmaceuticals, Inc.
On Monday March 1, 2010, 1:00 am
SAN DIEGO, March 1 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) announced today that it received a refuse to file letter from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for ANX-530 (vinorelbine injectable emulsion). In the letter, the FDA indicated that the data included in the initial submission from the intended commercial manufacturing site was insufficient to support a commercially-viable expiration dating period. FDA identified only the one chemistry, manufacturing and controls (CMC) reason for the refusal to file. ADVENTRX plans to meet with the FDA as soon as possible to discuss its response.
To support a commercially-viable expiration dating period, the stability data provided in the ANX-530 NDA met ICH filing requirements for a new drug. Site-specific stability data from lots manufactured at the intended commercial manufacturing site also were submitted in the NDA.
"We believed, following discussions with the FDA at a pre-NDA meeting, the stability data package included in our initial submission supported both NDA acceptance and appropriate expiration dating. However, we now expect FDA will require additional site-specific stability data to accept our application. Although we plan to discuss the particular filing requirements with the reviewing chemists, site-specific stability studies are already ongoing and our recent financings provide us the capital to continue this work and, we expect, resubmit the application," said Brian M. Culley, Chief Executive Officer at ADVENTRX.
"We will work closely with the Agency to understand its new requirements and define the path to a successful resubmission at the earliest possible time," Mr. Culley continued.
ADVENTRX submitted the NDA for ANX-530 on December 30, 2009. Based on current regulations, once an NDA is submitted to the FDA, FDA has 60 days to preliminarily review the NDA submission and assess whether the NDA is sufficiently complete to permit a substantive review. If it determines that the NDA is not sufficiently complete, the FDA issues a refuse to file letter to the applicant. ADVENTRX plans to request a meeting with the FDA as soon as possible to discuss its comments on the NDA submission and to reach an understanding on what would be required for the ANX-530 NDA to be accepted for review.
Conference Call and Webcast
ADVENTRX will hold a conference call on Monday, March 1, 2010 beginning at 9:00 a.m. Eastern time to review the developments discussed in this news release. Individuals interested in listening to the conference call may do so by dialing (866) 305-6438 for domestic callers, or (706) 679-7161 for international callers, or from the webcast on the investor relations section of the Company's Web site at www.adventrx.com. A 48-hour telephone replay will be available approximately one hour after the conclusion of the call by dialing (800) 642-1687 for domestic callers, or (706) 645-9291 for international callers, and entering reservation code 60223016. The webcast will be available on the Company's Web site for 14 days following the completion of the call.
http://investorshub.advfn.com/boards/read_msg.aspx?message_i…
schaut euch mal aria an, gute news heute
Im bid sind ca 5-6 Blöcke zu mit über 100000 Stücken
Sehr ungewöhnlich
Sehr ungewöhnlich
Zu diesen Kursen nachkaufen oder etwa komplett verkaufen ??
bin verunsichert
bin verunsichert
Antwort auf Beitrag Nr.: 39.034.045 von Plusquamperfekt am 01.03.10 16:36:52ich hab nachgekauft,wie man sieht steigt es auch schon wieder.
abgesehen davon man muss jetzt nicht alles schwarz malen,was vor ein paar wochen noch schön aussah .
in ein bis 2 monaten lachen wir über diesen wert .
jeder muss es für sich entscheiden,ich hab es gemacht,23000 stück in stuttgart für 0,14 cent.
abgesehen davon man muss jetzt nicht alles schwarz malen,was vor ein paar wochen noch schön aussah .
in ein bis 2 monaten lachen wir über diesen wert .
jeder muss es für sich entscheiden,ich hab es gemacht,23000 stück in stuttgart für 0,14 cent.
Antwort auf Beitrag Nr.: 39.034.195 von fatmamen am 01.03.10 16:52:10......... denk ich genau so......
Dass sind für mich persönlich kaufkurse...
Greez
Dass sind für mich persönlich kaufkurse...
Greez
Antwort auf Beitrag Nr.: 39.034.255 von sacha1978 am 01.03.10 16:57:10jetzt ist wohl eine kleine verschnaufpause angesagt,hat sie verdient.
wer nicht will hat schon zu viel verloren und mag nicht mehr.
sk 0,25 $ minimum meine prognose.
wer nicht will hat schon zu viel verloren und mag nicht mehr.
sk 0,25 $ minimum meine prognose.
Antwort auf Beitrag Nr.: 39.035.872 von Plusquamperfekt am 01.03.10 19:52:07hast recht,hat sich trotzdem gut gehalten!!!
werde drin bleiben,es wird weiter hoch gehn die tage,denn es ist nichts negatives über das produkt berichtet worden.
manchmal werden spielchen gespielt um die aktie interessant und in den blickwinkel zurücken.
natürlich nur meine meinung
werde drin bleiben,es wird weiter hoch gehn die tage,denn es ist nichts negatives über das produkt berichtet worden.
manchmal werden spielchen gespielt um die aktie interessant und in den blickwinkel zurücken.
natürlich nur meine meinung
Hoffe ihr Investierten habt euch in die Telefonkonferenz eingelinkt....denn wenn nein ist jeder selber Schuld....
*********************************************************
ADVENTRX will hold a conference call on Monday, March 1, 2010 beginning at 9:00 a.m. Eastern time to review the developments discussed in this news release. Individuals interested in listening to the conference call may do so by dialing (866) 305-6438 for domestic callers, or (706) 679-7161 for international callers, or from the webcast on the investor relations section of the Company's Web site at www.adventrx.com. A 48-hour telephone replay will be available approximately one hour after the conclusion of the call by dialing (800) 642-1687 for domestic callers, or (706) 645-9291 for international callers, and entering reservation code 60223016. The webcast will be available on the Company's Web site for 14 days following the completion of the call
**********************************************************
hatte es ja eingestellt...beobachte den Verlauf mit Interesse...( bin nicht investiert - aber immer offen für alle Entwicklungen am Markt )
*********************************************************
ADVENTRX will hold a conference call on Monday, March 1, 2010 beginning at 9:00 a.m. Eastern time to review the developments discussed in this news release. Individuals interested in listening to the conference call may do so by dialing (866) 305-6438 for domestic callers, or (706) 679-7161 for international callers, or from the webcast on the investor relations section of the Company's Web site at www.adventrx.com. A 48-hour telephone replay will be available approximately one hour after the conclusion of the call by dialing (800) 642-1687 for domestic callers, or (706) 645-9291 for international callers, and entering reservation code 60223016. The webcast will be available on the Company's Web site for 14 days following the completion of the call
**********************************************************
hatte es ja eingestellt...beobachte den Verlauf mit Interesse...( bin nicht investiert - aber immer offen für alle Entwicklungen am Markt )
Antwort auf Beitrag Nr.: 39.035.915 von fatmamen am 01.03.10 19:57:39Das sind keine Spielchen...oder liest Du keine News über diesen Wert...so lustig wird das nicht werden - die nächsten Tage - Biotechwerte sind mehr als empfindlich in diesen Tagen
Hmm...mal sehen wann ein Einstieg eventuell lohnt....vom 1 Jahreschart her "könnte " es bis 0,11-0,12 US runterlaufen...muss aber nicht.
Nun gut habs mal auf der Watch
Nun gut habs mal auf der Watch
Antwort auf Beitrag Nr.: 39.041.632 von Expertchen007 am 02.03.10 15:23:40von wegen 0,11-0,12 $ cent.
kurs stabilisiert sich,wie man sieht zwischen 0,18 und 0,20 $ cent.
falls du den 2 jahreschart betrachtest ,sieht es richtig bullisch aus.
das medikament ist natürlich auch wichtig,aber davon war nicht die rede beim letzten kommentar.
meine meinung,hier ist was zu holen !!!!
kurs stabilisiert sich,wie man sieht zwischen 0,18 und 0,20 $ cent.
falls du den 2 jahreschart betrachtest ,sieht es richtig bullisch aus.
das medikament ist natürlich auch wichtig,aber davon war nicht die rede beim letzten kommentar.
meine meinung,hier ist was zu holen !!!!
so,die 0,20 $ haben wir auch gleich
einsteigen wer noch mitfahren möchte,der fahrstuhl fährt nur noch hoch mit kleinen stop's zum ein-und aussteigen.
ich höre immer auf meinen dicken bauch,der hat in letzter zeit viel geld gebracht
fat mama
einsteigen wer noch mitfahren möchte,der fahrstuhl fährt nur noch hoch mit kleinen stop's zum ein-und aussteigen.
ich höre immer auf meinen dicken bauch,der hat in letzter zeit viel geld gebracht
fat mama
Antwort auf Beitrag Nr.: 39.045.139 von fatmamen am 02.03.10 21:27:06Na, ob wir die heute schaffen? Schon ein paarmal abgeprallt...
Auf TH geschlossen. Sehr gut.
Antwort auf Beitrag Nr.: 39.045.481 von strongbuyamitelo am 02.03.10 22:04:38schön nicht wahr ,mon amie.
gute nacht
fat mama
gute nacht
fat mama
Antwort auf Beitrag Nr.: 39.045.633 von fatmamen am 02.03.10 22:17:24die 0,20 $ scheint unsere mauer zu sein:
die werden wir aber schaffen,nur gedulden
ich hab zeit bis april wird noch ein reger handel stattfinden
die werden wir aber schaffen,nur gedulden
ich hab zeit bis april wird noch ein reger handel stattfinden
Antwort auf Beitrag Nr.: 39.052.789 von fatmamen am 03.03.10 19:02:10na sooooo schlecht sieht es wirklich nicht mehr aus !
Tja, morgen ist Freitag. Gibt´s Gewinnmitnahmen oder behalten die meisten über´s Wochenende?
Spannende Situation...
Spannende Situation...
Hatte sich wesentlich besser gehalten als ich erwartet hatte....aber fast kein Interesse mehr vorhanden......
Also die News heute kam überraschend...
yes....
ADVENTRX Receives Brand Name Acceptance for ANX-530
Buzz up! 0
Print
Companies:Adventrx Pharmaceuticals, Inc.
Related Quotes
Symbol Price Change
ANX 0.21 0.00
Press Release Source: ADVENTRX Pharmaceuticals, Inc. On Friday March 12, 2010, 8:00 am
SAN DIEGO, March 12 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) today announced that the U.S. Food and Drug Administration (FDA) has accepted the proposed proprietary name "Exelbine™" for the Company's product candidate ANX-530 (vinorelbine injectable emulsion).
"We are pleased with the FDA's response to our proprietary name request and look forward to continued regulatory progress on ANX-530," said Brian M. Culley, Chief Executive Officer of ADVENTRX.
Following completion of its review process, the FDA concluded that "Exelbine" is acceptable provided the information presented by ADVENTRX regarding the safety of interchanging ANX-530 with other vinorelbine injectable products is confirmed during review of an ANX-530 New Drug Application (NDA).
As previously announced, the Company submitted an NDA for ANX-530 to the FDA in December 2009. In March 2010, the Company announced that it had received a refusal-to-file letter from the FDA regarding its ANX-530 NDA submission. In the letter, the FDA indicated that the data included in the December 2009 NDA submission from the intended commercial manufacturing site was insufficient to support a commercially-viable expiration dating period. The FDA identified only this one chemistry, manufacturing and controls (CMC) reason for the refusal to file. ADVENTRX has requested a face-to-face meeting with the FDA to understand its requirements and define the path to a successful filing of an ANX-530 NDA at the earliest possible time.
http://finance.yahoo.com/news/ADVENTRX-Receives-Brand-Name-p…
ADVENTRX Receives Brand Name Acceptance for ANX-530
Buzz up! 0
Companies:Adventrx Pharmaceuticals, Inc.
Related Quotes
Symbol Price Change
ANX 0.21 0.00
Press Release Source: ADVENTRX Pharmaceuticals, Inc. On Friday March 12, 2010, 8:00 am
SAN DIEGO, March 12 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) today announced that the U.S. Food and Drug Administration (FDA) has accepted the proposed proprietary name "Exelbine™" for the Company's product candidate ANX-530 (vinorelbine injectable emulsion).
"We are pleased with the FDA's response to our proprietary name request and look forward to continued regulatory progress on ANX-530," said Brian M. Culley, Chief Executive Officer of ADVENTRX.
Following completion of its review process, the FDA concluded that "Exelbine" is acceptable provided the information presented by ADVENTRX regarding the safety of interchanging ANX-530 with other vinorelbine injectable products is confirmed during review of an ANX-530 New Drug Application (NDA).
As previously announced, the Company submitted an NDA for ANX-530 to the FDA in December 2009. In March 2010, the Company announced that it had received a refusal-to-file letter from the FDA regarding its ANX-530 NDA submission. In the letter, the FDA indicated that the data included in the December 2009 NDA submission from the intended commercial manufacturing site was insufficient to support a commercially-viable expiration dating period. The FDA identified only this one chemistry, manufacturing and controls (CMC) reason for the refusal to file. ADVENTRX has requested a face-to-face meeting with the FDA to understand its requirements and define the path to a successful filing of an ANX-530 NDA at the earliest possible time.
http://finance.yahoo.com/news/ADVENTRX-Receives-Brand-Name-p…
Jawohlllllllllllll...
yes we can.....
ich hab auf 30000 aufgestockt und war überzeugt das es steigen wird.
im april kommen noch verööffentlichungen und am weekend werden sich viele damit befassen.nächste woche wird es weiter steigen
nur meine persönliche einstellung zu diesem invest.
im april kommen noch verööffentlichungen und am weekend werden sich viele damit befassen.nächste woche wird es weiter steigen
nur meine persönliche einstellung zu diesem invest.
!!!!!
ADVENTRX Sets Meeting With FDA to Discuss ANX-530 NDA
SAN DIEGO, March 26 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) today announced that it will meet the U.S. Food and Drug Administration (FDA) in Washington D.C. during the last week of April 2010 to review the Company's New Drug Application (NDA) for ANX-530 (vinorelbine injectable emulsion) and the FDA's refusal-to-file letter.
ADVENTRX had requested a face-to-face meeting with the FDA to understand its requirements and define the path to a successful filing of an ANX-530 NDA at the earliest possible time.
"We look forward to meeting with the agency next month to clarify the necessary steps for filing the ANX-530 NDA this year," said Brian M. Culley, Chief Executive Officer of ADVENTRX.
ADVENTRX submitted an NDA for ANX-530 to the FDA in December 2009. The Company announced on March 1, 2010 that it had received a refusal-to-file letter from the FDA regarding that submission. In the letter, the FDA indicated that the data included in the December 2009 NDA submission from the intended commercial manufacturing site was insufficient to support a commercially-viable expiration dating period. The FDA identified only this one chemistry, manufacturing and controls (CMC) reason for the refusal to file. No clinical or nonclinical issues were identified.
http://pharmalive.com/News/Index.cfm?articleid=694004
ADVENTRX Sets Meeting With FDA to Discuss ANX-530 NDA
SAN DIEGO, March 26 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) today announced that it will meet the U.S. Food and Drug Administration (FDA) in Washington D.C. during the last week of April 2010 to review the Company's New Drug Application (NDA) for ANX-530 (vinorelbine injectable emulsion) and the FDA's refusal-to-file letter.
ADVENTRX had requested a face-to-face meeting with the FDA to understand its requirements and define the path to a successful filing of an ANX-530 NDA at the earliest possible time.
"We look forward to meeting with the agency next month to clarify the necessary steps for filing the ANX-530 NDA this year," said Brian M. Culley, Chief Executive Officer of ADVENTRX.
ADVENTRX submitted an NDA for ANX-530 to the FDA in December 2009. The Company announced on March 1, 2010 that it had received a refusal-to-file letter from the FDA regarding that submission. In the letter, the FDA indicated that the data included in the December 2009 NDA submission from the intended commercial manufacturing site was insufficient to support a commercially-viable expiration dating period. The FDA identified only this one chemistry, manufacturing and controls (CMC) reason for the refusal to file. No clinical or nonclinical issues were identified.
http://pharmalive.com/News/Index.cfm?articleid=694004
Adventrx Pharmaceuticals Inc., of San Diego, will meet with the FDA during the last week of April to discuss its new drug application for ANX-530 (vinorelbine injectable emulsion), which received a refuse-to-file letter earlier this month due to manufacturing deficiencies. ANX-530 is an emulsion of the chemotherapy drug vinorelbine, and Adventrx is seeking approval for non-small-cell lung cancer. (See BioWorld Today, March 2, 2010.)
Antwort auf Beitrag Nr.: 39.239.482 von Scania01 am 29.03.10 19:28:02geht wieder aufwärts.
... meet with the FDA during the last week of April
ist ja nicht mehr lang
... meet with the FDA during the last week of April
ist ja nicht mehr lang
Kann mir nicht helfen, irgend wer kauft die Bude auf.
Gehen laufen ganze Aktienpakete zu 100 oder 200 Stück über
den Tisch. So etwas habe ich noch nicht gesehen.
Gehen laufen ganze Aktienpakete zu 100 oder 200 Stück über
den Tisch. So etwas habe ich noch nicht gesehen.
Sieht sehr gut aus: RT über 0,26 USD
ANXADVENTRX Pharmaceuticals, Inc. (ANX) Pre-Market Trading Pre-Market Charts | After Hours Charts Apr. 14, 2010 Market Close: $ 0.2619 Pre-Market
Last: $ .268 Pre-Market
High: $ .27
Pre-Market
Volume: 42,882 Pre-Market
Low: $ .265
gehen wohl heute Richtung 0,30
Last: $ .268 Pre-Market
High: $ .27
Pre-Market
Volume: 42,882 Pre-Market
Low: $ .265
gehen wohl heute Richtung 0,30
hallo ,
so langsam kommt hier wieder bewegung rein . die nächsten 2 wochen werden sehr kurzweilig werden.demnächst werden sich hier wieder jede menge lustiges volk versammeln.
mfg
so langsam kommt hier wieder bewegung rein . die nächsten 2 wochen werden sehr kurzweilig werden.demnächst werden sich hier wieder jede menge lustiges volk versammeln.
mfg
Antwort auf Beitrag Nr.: 39.341.726 von teich61 am 15.04.10 15:48:41Stehen etwa News an ?
Es ist nicht zu übersehen, dass man sich für die letzte Woche im April positioniert.
Sehr schöner Anstieg.
Sehr schöner Anstieg.
Antwort auf Beitrag Nr.: 39.341.965 von Plusquamperfekt am 15.04.10 16:08:37das nächste mal informierst du dich aber selber
http://finance.yahoo.com/news/ADVENTRX-Sets-Meeting-With-prn…
http://finance.yahoo.com/news/ADVENTRX-Sets-Meeting-With-prn…
Pari wäre doch so bei 0,20 €
Antwort auf Beitrag Nr.: 39.344.759 von kunokuhn am 15.04.10 21:07:45So ist es.
Antwort auf Beitrag Nr.: 39.344.029 von strongbuyamitelo am 15.04.10 19:38:43joo, so ist es... bin mal Dienstag mit 100k rein...
immer schön vorsichtig
immer schön vorsichtig
Antwort auf Beitrag Nr.: 39.344.067 von teich61 am 15.04.10 19:41:39schon mal schön, das die FDA das Treffen überhaupt akzeptiert, nicht abgelehnt hat
ANXADVENTRX Pharmaceuticals, Inc. (ANX) Pre-Market Trading Pre-Market Charts | After Hours Charts Apr. 15, 2010 Market Close: $ 0.272 Pre-Market
Last: $ .2944 Pre-Market
High: $ .30
Pre-Market
Volume: 132,800 Pre-Market
Low: $ .289
könnte heute richtig gut abgehen
Last: $ .2944 Pre-Market
High: $ .30
Pre-Market
Volume: 132,800 Pre-Market
Low: $ .289
könnte heute richtig gut abgehen
ADVENTRX Resolves NYSE Amex Listing Deficiencies
Plans Reverse Stock Split to Address Exchange's Low Stock Price Concern
SAN DIEGO, April 16 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) today announced that it has resolved the stockholders' equity continued listing deficiencies originally identified by the NYSE Amex in a June 2009 letter to the Company. In part to address the NYSE Amex's requirement that the Company address its low stock price, ADVENTRX also announced that its Board of Directors has approved a 1-for-25 reverse split of its common stock, which was authorized by its stockholders at a special meeting held in August 2009. The Company's common stock will begin trading on a split adjusted basis on the NYSE Amex when the market opens on Monday, April 26, 2010.
In June 2009, the NYSE Amex notified the Company that it was not in compliance with the NYSE Amex's continued listing standards related to stockholders' equity. Through financing activity in 2009, ADVENTRX increased its stockholder's equity to approximately $6.7 million as of December 31, 2009, which exceeds continued listing standards related to stockholders' equity. In April 2010, the NYSE Amex notified the Company that, based on a review of publicly available information, ADVENTRX has resolved the continued listing deficiencies originally identified in the June 2009 letter. According to the April 2010 letter, the Company must demonstrate compliance with the continued listing standards for two consecutive quarters and/or by December 1, 2010, otherwise the NYSE Amex may initiate delisting procedures. In part as a result of a financing completed in January 2010, the Company anticipates complying with continued listing standards related to stockholders' equity at March 31, 2010.
The reverse stock split is intended to satisfy the NYSE Amex's determination in the June 2009 letter that it is appropriate for the Company to effect a reverse stock split to address its low price per share and that, if a reverse stock split is not completed within a reasonable amount of time, the NYSE Amex may initiate delisting procedures. The Company also believes that a higher share price could broaden ADVENTRX's appeal to investors, in addition to reducing per share transaction fees and certain administrative costs.
The reverse split will be effective upon the close of trading on Friday, April 23, 2010, and the Company's common stock will begin trading on a split adjusted basis on the NYSE Amex when the market opens on Monday, April 26, 2010. The reverse split will reduce the number of shares of the Company's common stock outstanding from approximately 257 million to approximately 10.3 million. Proportional adjustments will be made to ADVENTRX's outstanding stock options, warrants and other equity awards and to its equity compensation plans. Par value and the number of authorized shares of common stock will not change. The Company will not issue any fractional shares. Stockholders will receive cash in lieu of fractional shares to which they would otherwise be entitled.
Information for Stockholders regarding Reverse Stock Split
Registered holders of ADVENTRX common stock will receive a letter of transmittal shortly after the effective date of the reverse stock split with instructions for the exchange of their old stock certificates or the electronic adjustment of their holdings through the direct registration system, as applicable. American Stock Transfer and Trust Company will act as the exchange agent and can be contacted at (877) 2486417. Stockholders with shares in brokerage accounts will be contacted by their brokers with instructions.
About ADVENTRX Pharmaceuticals
ADVENTRX Pharmaceuticals is a specialty pharmaceutical company whose product candidates are designed to improve the performance of existing cancer treatments by addressing limitations associated principally with their safety and use. More information can be found on the Company's web site at www.adventrx.com.
Forward Looking Statements
ADVENTRX cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks and assumptions that, if they materialize or do not prove to be accurate, could cause ADVENTRX's results to differ materially from historical results or those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the risk that ADVENTRX will not meet the NYSE Amex's stockholders' equity continued listing standards for two consecutive quarters and/or by December 1, 2010 and that the NYSE Amex staff will commence delisting proceedings; the risk of negative market reaction following announcement and/or implementation of the planned reverse stock split, resulting in stock price decline; the risk of unexpected delays in completing the reverse stock split; the risk that NYSE Amex will commence delisting proceedings based on a future low selling price per share; the risk that ADVENTRX will pursue development activities at levels or on timelines, or will incur unexpected expenses, that shortens the period through which it is able to comply with NYSE Amex continued listing requirements related to stockholders' equity; the risk that ADVENTRX will be unable to raise sufficient additional capital to continue to develop, seek regulatory approval of and commercialize its product candidates while maintaining compliance with NYSE Amex continued listing requirements related to stockholders' equity; the risk of difficulties or delays in manufacturing, obtaining regulatory approval for and marketing ADVENTRX's lead product candidates; ADVENTRX's reliance on the performance of third parties to assist in the conduct of its bioequivalence trials, regulatory submissions, CMC activities and other important aspects of its product candidate development programs, and that such third parties may fail to perform as expected; and other risks and uncertainties more fully described in ADVENTRX's press releases and periodic filings with the Securities and Exchange Commission, including its annual report on Form 10-K for the year ended December 31, 2009. ADVENTRX's public filings with the Securities and Exchange Commission are available at http://www.sec.gov/.
You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date when made. ADVENTRX does not intend to update any forward-looking statement as set forth in this press release to reflect events or circumstances arising after the date on which it was made.
Plans Reverse Stock Split to Address Exchange's Low Stock Price Concern
SAN DIEGO, April 16 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) today announced that it has resolved the stockholders' equity continued listing deficiencies originally identified by the NYSE Amex in a June 2009 letter to the Company. In part to address the NYSE Amex's requirement that the Company address its low stock price, ADVENTRX also announced that its Board of Directors has approved a 1-for-25 reverse split of its common stock, which was authorized by its stockholders at a special meeting held in August 2009. The Company's common stock will begin trading on a split adjusted basis on the NYSE Amex when the market opens on Monday, April 26, 2010.
In June 2009, the NYSE Amex notified the Company that it was not in compliance with the NYSE Amex's continued listing standards related to stockholders' equity. Through financing activity in 2009, ADVENTRX increased its stockholder's equity to approximately $6.7 million as of December 31, 2009, which exceeds continued listing standards related to stockholders' equity. In April 2010, the NYSE Amex notified the Company that, based on a review of publicly available information, ADVENTRX has resolved the continued listing deficiencies originally identified in the June 2009 letter. According to the April 2010 letter, the Company must demonstrate compliance with the continued listing standards for two consecutive quarters and/or by December 1, 2010, otherwise the NYSE Amex may initiate delisting procedures. In part as a result of a financing completed in January 2010, the Company anticipates complying with continued listing standards related to stockholders' equity at March 31, 2010.
The reverse stock split is intended to satisfy the NYSE Amex's determination in the June 2009 letter that it is appropriate for the Company to effect a reverse stock split to address its low price per share and that, if a reverse stock split is not completed within a reasonable amount of time, the NYSE Amex may initiate delisting procedures. The Company also believes that a higher share price could broaden ADVENTRX's appeal to investors, in addition to reducing per share transaction fees and certain administrative costs.
The reverse split will be effective upon the close of trading on Friday, April 23, 2010, and the Company's common stock will begin trading on a split adjusted basis on the NYSE Amex when the market opens on Monday, April 26, 2010. The reverse split will reduce the number of shares of the Company's common stock outstanding from approximately 257 million to approximately 10.3 million. Proportional adjustments will be made to ADVENTRX's outstanding stock options, warrants and other equity awards and to its equity compensation plans. Par value and the number of authorized shares of common stock will not change. The Company will not issue any fractional shares. Stockholders will receive cash in lieu of fractional shares to which they would otherwise be entitled.
Information for Stockholders regarding Reverse Stock Split
Registered holders of ADVENTRX common stock will receive a letter of transmittal shortly after the effective date of the reverse stock split with instructions for the exchange of their old stock certificates or the electronic adjustment of their holdings through the direct registration system, as applicable. American Stock Transfer and Trust Company will act as the exchange agent and can be contacted at (877) 2486417. Stockholders with shares in brokerage accounts will be contacted by their brokers with instructions.
About ADVENTRX Pharmaceuticals
ADVENTRX Pharmaceuticals is a specialty pharmaceutical company whose product candidates are designed to improve the performance of existing cancer treatments by addressing limitations associated principally with their safety and use. More information can be found on the Company's web site at www.adventrx.com.
Forward Looking Statements
ADVENTRX cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks and assumptions that, if they materialize or do not prove to be accurate, could cause ADVENTRX's results to differ materially from historical results or those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the risk that ADVENTRX will not meet the NYSE Amex's stockholders' equity continued listing standards for two consecutive quarters and/or by December 1, 2010 and that the NYSE Amex staff will commence delisting proceedings; the risk of negative market reaction following announcement and/or implementation of the planned reverse stock split, resulting in stock price decline; the risk of unexpected delays in completing the reverse stock split; the risk that NYSE Amex will commence delisting proceedings based on a future low selling price per share; the risk that ADVENTRX will pursue development activities at levels or on timelines, or will incur unexpected expenses, that shortens the period through which it is able to comply with NYSE Amex continued listing requirements related to stockholders' equity; the risk that ADVENTRX will be unable to raise sufficient additional capital to continue to develop, seek regulatory approval of and commercialize its product candidates while maintaining compliance with NYSE Amex continued listing requirements related to stockholders' equity; the risk of difficulties or delays in manufacturing, obtaining regulatory approval for and marketing ADVENTRX's lead product candidates; ADVENTRX's reliance on the performance of third parties to assist in the conduct of its bioequivalence trials, regulatory submissions, CMC activities and other important aspects of its product candidate development programs, and that such third parties may fail to perform as expected; and other risks and uncertainties more fully described in ADVENTRX's press releases and periodic filings with the Securities and Exchange Commission, including its annual report on Form 10-K for the year ended December 31, 2009. ADVENTRX's public filings with the Securities and Exchange Commission are available at http://www.sec.gov/.
You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date when made. ADVENTRX does not intend to update any forward-looking statement as set forth in this press release to reflect events or circumstances arising after the date on which it was made.
Antwort auf Beitrag Nr.: 39.349.981 von zuzlhuba am 16.04.10 14:06:01der R-Split von 25:1 ist wohl doch schon länger bekannt...
offensichtlich finden das die Anleger nicht so Klasse RT Pre Market 0,25
offensichtlich finden das die Anleger nicht so Klasse RT Pre Market 0,25
Das ist absolute Sch....!!!
Antwort auf Beitrag Nr.: 39.351.298 von Scania01 am 16.04.10 16:19:52du sagst es
Über 20 Millionen Stück über den Tisch gegangen.
Blanke Panik.
Blanke Panik.
Antwort auf Beitrag Nr.: 39.352.344 von Scania01 am 16.04.10 17:42:46wird nun gesplittet oder nicht
weist du da mehr
weist du da mehr
Antwort auf Beitrag Nr.: 39.352.360 von kunokuhn am 16.04.10 17:44:27Hast du die Meldung nicht gelesen R/S 1 : 25.
Wenn du 25 Aktien hast, hast du danach nur noch eine.
Der Kurs ist zwar entsprechend höher. Aber danach
fällt meistens der Kurs.
Wenn du 25 Aktien hast, hast du danach nur noch eine.
Der Kurs ist zwar entsprechend höher. Aber danach
fällt meistens der Kurs.
Oder der Kurs fällt vorher schon, wie man es jetzt erlebt.
Daher die Panik jetzt.
Daher die Panik jetzt.
am 26.04.2010 wird der R-Split durchgeführt. Der Handel eröffnet dann entsprechnend heutigen Kurs 0,21$ bei 5,25$
Antwort auf Beitrag Nr.: 39.353.288 von SchnerJrg am 16.04.10 19:25:04Wurde nicht schon mal ein R/S durch geführt?
Ich dächte das war im Jahr 2003. Danach stand die
Aktie über 2 Dollar und wurde bis 1 Dollar nach unten gedrückt.
Danach stieg sie wieder.
Kann man also nur noch aussteigen und in einen Jahr
mal wieder reinschauen, ob sich ein Einstieg wieder
lohnt.
Ich dächte das war im Jahr 2003. Danach stand die
Aktie über 2 Dollar und wurde bis 1 Dollar nach unten gedrückt.
Danach stieg sie wieder.
Kann man also nur noch aussteigen und in einen Jahr
mal wieder reinschauen, ob sich ein Einstieg wieder
lohnt.
Antwort auf Beitrag Nr.: 39.354.035 von Scania01 am 16.04.10 21:20:10ist derselbe käse wie bei vielen Pharma und Biotechs
jahrzehnte lange forschungen und bei einem von 100 gehts ab
habe ANX schon über 1 Jahr in der watch....
jahrzehnte lange forschungen und bei einem von 100 gehts ab
habe ANX schon über 1 Jahr in der watch....
Antwort auf Beitrag Nr.: 39.353.288 von SchnerJrg am 16.04.10 19:25:04der kurs wird vorher schon fallen-also vor dem split.
man koennte sich auch fragen warum man gerade 1-25 splittet.
also bei der amex/nasdaq muss man mind 1 dollar/share vorweissen,sonst fliegt man nach gewisser zeit raus[delisting].also ist noch genug raum nach unten,den das unternehmen anscheinend auch einkalkuliert,sonst wuerde man 1-10 oder tiefer splitten.
die andere gefahr ist natuerlich auch wieder sehr gross,das man durch den split nur noch 10 mio shares am markt hat und bei verzoegerungen hier leicht durch verwaesserung-[dilution]
zu neuem geld kommen wird.
ich denke mir jetzt folgendes.
entweder die halten den kurs kuenstlich auf dem level und starten nach split tatsaechlich bei 5 dollar/share und anschliessend gehts straff runter auf 1,50 und danach wieder hoch,oder das spielchen laeuft gerade andersrum.
man muss anx die naechsten 2 wochen beobachten.jedenfalls sagt mir meine erfahrung das sich zwar an der situation nichts aendert,aber 5 dollar niemals halten werden und man extrem short gehen wird,wenns denn so kommt.
da duerften die naechsten wochen paar % fuer uns drin sein.
ich warte ab und steh an der seitenlinie-der derzeitige kurs ist jedenfalls viel zu teuer nach split[rein optisch]und das wird man ausnutzen.
alles in allem keine gute news fuer longs.
mfg sawasdee
man koennte sich auch fragen warum man gerade 1-25 splittet.
also bei der amex/nasdaq muss man mind 1 dollar/share vorweissen,sonst fliegt man nach gewisser zeit raus[delisting].also ist noch genug raum nach unten,den das unternehmen anscheinend auch einkalkuliert,sonst wuerde man 1-10 oder tiefer splitten.
die andere gefahr ist natuerlich auch wieder sehr gross,das man durch den split nur noch 10 mio shares am markt hat und bei verzoegerungen hier leicht durch verwaesserung-[dilution]
zu neuem geld kommen wird.
ich denke mir jetzt folgendes.
entweder die halten den kurs kuenstlich auf dem level und starten nach split tatsaechlich bei 5 dollar/share und anschliessend gehts straff runter auf 1,50 und danach wieder hoch,oder das spielchen laeuft gerade andersrum.
man muss anx die naechsten 2 wochen beobachten.jedenfalls sagt mir meine erfahrung das sich zwar an der situation nichts aendert,aber 5 dollar niemals halten werden und man extrem short gehen wird,wenns denn so kommt.
da duerften die naechsten wochen paar % fuer uns drin sein.
ich warte ab und steh an der seitenlinie-der derzeitige kurs ist jedenfalls viel zu teuer nach split[rein optisch]und das wird man ausnutzen.
alles in allem keine gute news fuer longs.
mfg sawasdee
Antwort auf Beitrag Nr.: 39.354.978 von sawasdeekhrab am 17.04.10 06:26:58dann haben wir unsere Kohle verbrannt
Wenn wir unter 0,10€ sind lege ich nochmal ne kleine Posi nach.
Ich denke auf längere Sicht könnte sich hier eine gute Chance ergeben.
Was denkt ihr?
Lg Lizu
Ich denke auf längere Sicht könnte sich hier eine gute Chance ergeben.
Was denkt ihr?
Lg Lizu
Mal eine Fachfrage.
DAS Medikament ANX-530 ist so wie ich verstehe ein Generika.
Da aber der Wirkstoff verbessert wurde müsste
dieses Medikament wieder Patentrechtlich geschützt werden.
Da man ja reichlich in Entwicklung und Forschung investiert hat.
Ist das richtig?
DAS Medikament ANX-530 ist so wie ich verstehe ein Generika.
Da aber der Wirkstoff verbessert wurde müsste
dieses Medikament wieder Patentrechtlich geschützt werden.
Da man ja reichlich in Entwicklung und Forschung investiert hat.
Ist das richtig?
Antwort auf Beitrag Nr.: 39.360.398 von Lizu am 19.04.10 12:43:26Schwachsinn
Antwort auf Beitrag Nr.: 39.360.949 von Scania01 am 19.04.10 14:23:20rein provokative frage bzw. stumpfer versuch...
Antwort auf Beitrag Nr.: 39.361.145 von giesarazu am 19.04.10 14:58:15 Nach dem Motto, schlecht gepusht ist auch gepusht.
Wer ist verrückt genug vor dem R/S zu kaufen...ich sicher nicht......sollte man nach R/ S dann verfolgen...dürfte noch heftig werden bis zum R/S
Antwort auf Beitrag Nr.: 39.360.398 von Lizu am 19.04.10 12:43:26kennst dich wohl nicht so richtig aus
was jetzt passiert
was jetzt passiert
Antwort auf Beitrag Nr.: 39.361.574 von kunokuhn am 19.04.10 16:00:20Na ich denke soweit liegt der möglicherweise gar nicht weg vom Kursziel.....kann noch richtig heftig werden...ich schau es mir gemütlich an
Ich amüsiere mich auch, über die Kleingeld Jäger.
Antwort auf Beitrag Nr.: 39.360.398 von Lizu am 19.04.10 12:43:26die wirst du nie bekommen ,wenn sie so schlecht waere ,muesste sie ja heute schon gefallen sein,meine meinung die geht noch maechtig nach oben ,meine meinung keine empfehlung.
Antwort auf Beitrag Nr.: 39.361.574 von kunokuhn am 19.04.10 16:00:20Kannst du mich denn aufklären?
Antwort auf Beitrag Nr.: 39.363.300 von Lizu am 19.04.10 19:56:33wird wohl vor dem Splitt abwärts gehen
und nach dem Splitt nochmal runter
und nach dem Splitt nochmal runter
Antwort auf Beitrag Nr.: 39.363.538 von kunokuhn am 19.04.10 20:28:12das sind doch alles nur hypothesen
am besten wir lassen uns überraschen
ich habe auch schon splits erlebt bei denen es nicht weiter runter ging
also sage ich mal.....hoffen wir das beste
am besten wir lassen uns überraschen
ich habe auch schon splits erlebt bei denen es nicht weiter runter ging
also sage ich mal.....hoffen wir das beste
Antwort auf Beitrag Nr.: 39.363.538 von kunokuhn am 19.04.10 20:28:12Ja, das habe ich soweit verstanden.
Aber kannst du mir das auch begründen?
Warum wird das deiner Meinung nach passieren?
Aber kannst du mir das auch begründen?
Warum wird das deiner Meinung nach passieren?
Antwort auf Beitrag Nr.: 39.362.766 von zorro8 am 19.04.10 18:32:30in dieser aktie ist der miliardaer icahn und viele shorties drin. ,dass wird der highflyer der woche meine meinung ,keine empfehlung.
Antwort auf Beitrag Nr.: 39.364.223 von zorro8 am 19.04.10 22:05:47
hallo zorro8,
welche woche meinst du ???????
grüße
lotto
hallo zorro8,
welche woche meinst du ???????
grüße
lotto
AHA Splitt durchgeführt...dachte schon wegen Taxe 4,08 US...oder wie ?????
in welche verhältnis wurde denn gesplittet?
kurs momentan 4,38usd!
danke!
kurs momentan 4,38usd!
danke!
Werde ich mal mit Interesse verfolgen diese TAge....Pari zu Splitt wäre rund 4,50 US$ gewesen..bei 25- er Splitt...Basis 0,18 US$
Antwort auf Beitrag Nr.: 39.401.603 von Tommi33 am 26.04.10 15:50:24
also ca. 30% runter vom kurs 0,15 euro?
danke!
also ca. 30% runter vom kurs 0,15 euro?
danke!
Antwort auf Beitrag Nr.: 39.401.675 von gled77 am 26.04.10 15:58:13Ne Basis ist 0,18 US$....müssten so rund 7-8 % bis jetzt sein
Antwort auf Beitrag Nr.: 39.401.675 von gled77 am 26.04.10 15:58:13gibts selten mal das nach Splitt - Gewinne gemacht werden...na ja wurde ja lange angekündigt...
Kein (noch nicht ) Handel in D oder neue WKN ???
Antwort auf Beitrag Nr.: 39.402.012 von Expertchen007 am 26.04.10 16:33:55WKN A1CWVV
aber noch kein Handel
aber noch kein Handel
Antwort auf Beitrag Nr.: 39.402.819 von kunokuhn am 26.04.10 18:04:43bin mal gespannt wie das weitergeht...ist ein guter Erfahrungswert mit dem Splitt im Biotech Sektor..hier die neue WKN ( danke für den Hinweis )
http://www.wallstreet-online.de/aktien/9218707/diskussionen.…
2,90€ = 0,116 € vor Splitt - heftiger Abschlag
http://www.wallstreet-online.de/aktien/9218707/diskussionen.…
2,90€ = 0,116 € vor Splitt - heftiger Abschlag
ADVENTRX to Resubmit ANX-530 NDA in the Fourth Quarter of 2010
SAN DIEGO, April 27 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) today announced that, based on information received from the U.S. Food and Drug Administration (FDA), the Company plans to resubmit its New Drug Application (NDA) for ANX-530 (vinorelbine injectable emulsion), or Exelbine™, in the fourth quarter of 2010.
"We are pleased to have clarified with the FDA certain matters concerning the stability data necessary to file the Exelbine NDA," said Brian M. Culley, Chief Executive Officer of ADVENTRX. "The studies that will generate the stability data from our intended commercial manufacturing site that the FDA wishes to see are ongoing, and we plan to resubmit the NDA in the fourth quarter of this year."
ADVENTRX submitted an NDA for ANX-530 to the FDA in December 2009. The Company announced on March 1, 2010 that it had received a refusal-to-file letter from the FDA regarding that submission. In the letter, the FDA indicated that the data included in the December 2009 NDA submission from the intended commercial manufacturing site was insufficient to support a commercially-viable expiration dating period. The FDA identified only this one chemistry, manufacturing and controls (CMC) reason for the refusal to file. No clinical or nonclinical issues were identified.
SAN DIEGO, April 27 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) today announced that, based on information received from the U.S. Food and Drug Administration (FDA), the Company plans to resubmit its New Drug Application (NDA) for ANX-530 (vinorelbine injectable emulsion), or Exelbine™, in the fourth quarter of 2010.
"We are pleased to have clarified with the FDA certain matters concerning the stability data necessary to file the Exelbine NDA," said Brian M. Culley, Chief Executive Officer of ADVENTRX. "The studies that will generate the stability data from our intended commercial manufacturing site that the FDA wishes to see are ongoing, and we plan to resubmit the NDA in the fourth quarter of this year."
ADVENTRX submitted an NDA for ANX-530 to the FDA in December 2009. The Company announced on March 1, 2010 that it had received a refusal-to-file letter from the FDA regarding that submission. In the letter, the FDA indicated that the data included in the December 2009 NDA submission from the intended commercial manufacturing site was insufficient to support a commercially-viable expiration dating period. The FDA identified only this one chemistry, manufacturing and controls (CMC) reason for the refusal to file. No clinical or nonclinical issues were identified.
wenn dass so weiter geht sind die im 3. Quartal wieder bei 0,30 Dollar
Hallo zusammen,
hab mir mal erlaubt nen neuen Thread mit der neuen WKN aufzumachen.
Zu finden hier -> http://www.wallstreet-online.de/diskussion/1157423-neustebei…
LG Tommi
hab mir mal erlaubt nen neuen Thread mit der neuen WKN aufzumachen.
Zu finden hier -> http://www.wallstreet-online.de/diskussion/1157423-neustebei…
LG Tommi
Beitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Meistdiskutiert
Wertpapier | Beiträge | |
---|---|---|
96 | ||
53 | ||
32 | ||
26 | ||
22 | ||
20 | ||
18 | ||
14 | ||
13 | ||
10 |
Wertpapier | Beiträge | |
---|---|---|
10 | ||
8 | ||
8 | ||
7 | ||
7 | ||
6 | ||
6 | ||
6 | ||
6 | ||
6 |